Automation divestment lifts NPAT 52%, continuing ops grow only 6%

Comparable note: HY21 was selected on an inferred basis rather than an exact same-period filing match.

What changed

LIC's headline numbers diverge sharply depending on whether continuing or total operations are read. On a continuing-operations basis (the company's own primary framing), revenue grew 5.4% to $169.4m from a restated $160.7m, EBITDA rose 4.7% to $61.2m, and NPAT from continuing operations rose 6.2% to $35.6m. On a total-reported basis used by the like-for-like extraction, total revenue was effectively flat (+0.1% versus $169.7m) and EBITDA was +2.0% versus a previously reported $60.0m.

Reported NPAT jumped 51.8% to $50.8m, but $15.2m of that was a post-tax gain from divesting the Automation business (recorded as a discontinued operation). PBT from continuing operations was $49.6m, struck on an effective tax rate of 28.3%. Operating cash flow doubled to $21.9m from $10.8m, capex ran at $10.7m (6.3% of revenue), and pre-lease free cash flow was about $11.2m. The balance sheet strengthened further: cash rose to $48.6m, gross borrowings remained at zero, total assets reached $428.4m, and equity grew to $327.3m.

What matters

• The 52% NPAT growth is mostly transaction-driven. Strip out the $15.2m Automation divestment gain and continuing-ops NPAT growth is 6.2%. PBT (continuing) at $49.6m is the cleaner core-earnings read, and there is no clean prior PBT comparable disclosed.
• Cash conversion improved materially. OCF/EBITDA moved from roughly 18% to roughly 36%. The company had previously flagged that HY21 was depressed by tax payment and customer receipts timing, so part of this is a base effect rather than structural improvement.
• Mix is concentrated in high-margin genetics and software. NZ market genetics generated 57.6% of revenue at an estimated 67.8% segment PBT margin, and farm software contributed 15.5% at an estimated 74.1% margin. The earnings base is leveraged to spring AB demand.

Expectations

No quantitative guidance, forward-work figure, or stated target was disclosed in the supplied materials. Seasonality is severe and asymmetric: HY21 NPAT of $33.4m was 146% of full-year FY21 NPAT of $22.9m, implying H2 of FY21 was loss-making by roughly $10.5m. Annualising HY22 revenue to ~$338.7m therefore overstates the run-rate; the seasonally weak H2 will pull the FY22 outcome materially below double the H1 print, even before considering that Automation revenue will not recur in continuing operations.

The release does support a stronger H1 base entering H2 than HY21 did, with continuing-ops earnings up mid single-digit and the balance sheet debt-free. It does not support an extrapolation to FY22 NPAT, given the discontinued-ops gain and seasonal H2 loss pattern.

Quality of result

The continuing-operations result is reasonably durable: revenue +5.4%, EBITDA +4.7%, and NPAT +6.2% on a like-for-like restated basis, with a normal 28.3% effective tax rate and no obvious tax distortion. The headline NPAT result is not durable — the $15.2m Automation divestment gain is a one-off and inflates reported NPAT growth from roughly 6% to 52%.

The doubling of operating cash flow looks part-real, part-base-effect: the prior period was held back by tax timing per LIC's own HY21 commentary, so some of the $11.1m OCF improvement is normalisation rather than fresh operating progress. Pre-lease FCF of $11.2m only covers about 22% of reported NPAT — the remainder of the bottom line sits in the divestment gain and in working-capital and tax-timing movements rather than recurring cash earnings.

Unresolved

• The interim dividend amount per share and payout policy versus the FY21 12.51c distribution were not in the extracted figures.
• Use of the $48.6m net cash position post-Automation divestment is not addressed: dividend top-up, M&A, or retention.
• Restated continuing-ops segment comparables for HY21 are not disclosed in the extract, so the 5.4% revenue and 4.7% EBITDA growth cannot be decomposed by segment.
• Working-capital days and trade-debtor balances were not supplied, limiting confirmation of how much of the OCF improvement is genuinely operational.
• The selection diagnostics flag that prior-period and FY21 anchor matching is "inferred, low confidence", so some comparability headers in the extraction differ from the company's own restated framing.

This briefing cannot assess management's intended deployment of divestment proceeds, the underlying volume-versus-price drivers in NZ market genetics, or the FY22 dividend trajectory.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.